JP2018508469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508469A5 JP2018508469A5 JP2017533956A JP2017533956A JP2018508469A5 JP 2018508469 A5 JP2018508469 A5 JP 2018508469A5 JP 2017533956 A JP2017533956 A JP 2017533956A JP 2017533956 A JP2017533956 A JP 2017533956A JP 2018508469 A5 JP2018508469 A5 JP 2018508469A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- patient
- expression level
- egfr
- fgfr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021099307A JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096741P | 2014-12-24 | 2014-12-24 | |
| US62/096,741 | 2014-12-24 | ||
| PCT/US2015/000237 WO2016105503A1 (en) | 2014-12-24 | 2015-12-23 | Therapeutic, diagnostic and prognostic methods for cancer of the bladder |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099307A Division JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508469A JP2018508469A (ja) | 2018-03-29 |
| JP2018508469A5 true JP2018508469A5 (enExample) | 2019-01-31 |
| JP6900314B2 JP6900314B2 (ja) | 2021-07-07 |
Family
ID=55275150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533956A Active JP6900314B2 (ja) | 2014-12-24 | 2015-12-23 | 膀胱癌の治療、診断、及び予後判定方法 |
| JP2021099307A Pending JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021099307A Pending JP2021169451A (ja) | 2014-12-24 | 2021-06-15 | 膀胱癌の治療、診断、及び予後判定方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170306418A1 (enExample) |
| EP (2) | EP3699290A1 (enExample) |
| JP (2) | JP6900314B2 (enExample) |
| KR (1) | KR20170095893A (enExample) |
| CN (1) | CN107223163A (enExample) |
| AU (1) | AU2015371312B2 (enExample) |
| CA (1) | CA2969830A1 (enExample) |
| HK (1) | HK1244847A1 (enExample) |
| IL (1) | IL252796B (enExample) |
| MX (1) | MX394474B (enExample) |
| MY (1) | MY188938A (enExample) |
| RU (1) | RU2739942C2 (enExample) |
| SG (1) | SG11201704852SA (enExample) |
| WO (1) | WO2016105503A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| TWI736437B (zh) | 2010-11-30 | 2021-08-11 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| BR112017005598A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
| WO2016091849A2 (en) * | 2014-12-11 | 2016-06-16 | Bayer Pharma Aktiengesellschaft | Use of pan fgfr inhibitors and method of identifying patients with cancer eligible for treatment with a pan fgfr inhibitor |
| WO2016154058A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| EP3365335B1 (en) | 2015-10-23 | 2024-02-14 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| US20180165599A1 (en) * | 2016-12-12 | 2018-06-14 | Business Objects Software Ltd. | Predictive model integration |
| WO2019055622A1 (en) * | 2017-09-14 | 2019-03-21 | Siemens Healthcare Diagnostics Inc. | ADHESIVE POLYMER CONTAINING MEMBRANES FOR IN VITRO DIAGNOSTIC DEVICES |
| CN110115758B (zh) * | 2018-02-05 | 2021-05-11 | 中山大学 | Pik3ip1蛋白在调节t细胞反应和制备抗肿瘤药物中的应用 |
| CN108676884A (zh) * | 2018-06-04 | 2018-10-19 | 海口市人民医院（中南大学湘雅医学院附属海口医院） | 一种用于预测膀胱癌的肿瘤标志物 |
| CA3111401A1 (en) * | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| CN111289748A (zh) * | 2018-12-08 | 2020-06-16 | 惠州市中大惠亚医院 | ErbB3蛋白在制备膀胱癌无创诊断产品中的应用 |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| US20220145403A1 (en) * | 2019-04-12 | 2022-05-12 | Stratifyer Molecular Pathology Gmbh | Method of classifying a sample based on determination of fgfr |
| CN110055331B (zh) * | 2019-05-10 | 2023-05-02 | 人和未来生物科技（长沙）有限公司 | 一种用于膀胱癌辅助诊断或筛查的试剂盒及其应用 |
| WO2021010326A1 (ja) * | 2019-07-12 | 2021-01-21 | 中外製薬株式会社 | 抗変異型ｆｇｆｒ３抗体およびその使用 |
| US20230115945A1 (en) | 2019-12-30 | 2023-04-13 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN111269983A (zh) * | 2020-02-21 | 2020-06-12 | 深圳市众循精准医学研究院 | 一种膀胱癌基因扩增的fish检测方法、探针及试剂盒 |
| US20230108495A1 (en) * | 2020-03-18 | 2023-04-06 | The Regents Of The University Of California | Risk-stratification of meningioma patients |
| CN111679076A (zh) * | 2020-06-15 | 2020-09-18 | 吉林医药学院 | 一种用于检测cyclinD1和BCL-2抗体的检测试剂盒 |
| US20230178177A1 (en) * | 2020-06-30 | 2023-06-08 | Northwestern University | A single patient classifier for t1 high grade bladder cancer |
| GB2597332A (en) * | 2020-07-20 | 2022-01-26 | Institute Of Cancer Res | Prognostic and treatment response predictive method |
| MX2023007793A (es) | 2020-12-30 | 2023-09-22 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas. |
| EP4291902A4 (en) * | 2021-02-10 | 2025-01-08 | Foundation Medicine, Inc. | BIOMARKERS FOR CANCER TREATMENT |
| EP4297873A1 (en) | 2021-02-26 | 2024-01-03 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| WO2023287839A2 (en) * | 2021-07-13 | 2023-01-19 | Brown University | Urinary tract cancer treatment guided by mutational landscape |
| JP2023023327A (ja) * | 2021-08-05 | 2023-02-16 | 国立大学法人大阪大学 | 腫瘍のサブタイプ決定方法及びその応用、並びにサブタイプ決定のための方法 |
| IT202200001817A1 (it) | 2022-02-02 | 2023-08-02 | Aizoon S R L | Procedimento per la prognosi di una malattia in seguito ad un trattamento terapeutico, relativo sistema e prodotto informatico |
| IT202200005861A1 (it) | 2022-03-24 | 2023-09-24 | Aizoon S R L | Procedimento per stimare una variabile di interesse associata ad una data malattia in funzione di una pluralità di diversi dati omici, relativo dispositivo e prodotto informatico |
| CN115343474B (zh) * | 2022-06-27 | 2024-12-27 | 陕西佰美基因股份有限公司 | Ckap4蛋白的应用、产品、表达干扰试剂及预后模型构建方法 |
| IL317558A (en) | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| AU2023300357A1 (en) | 2022-06-29 | 2025-01-09 | Tyra Biosciences, Inc. | Polymorphic compounds and uses thereof |
| US20240028964A1 (en) | 2022-07-25 | 2024-01-25 | Aizoon S.r.l. | Method for providing a clinical decision support, corresponding system for providing a clinical decision support, and computer program product |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| AU2024400764A1 (en) | 2023-12-15 | 2026-07-09 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
| WO2026035809A1 (en) | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
| WO2026143223A2 (en) | 2024-12-27 | 2026-07-02 | Tyra Biosciences, Inc. | Fgfr inhibitors |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5527676A (en) | 1989-03-29 | 1996-06-18 | The Johns Hopkins University | Detection of loss of the wild-type P53 gene and kits therefor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| AU693475B2 (en) | 1993-10-01 | 1998-07-02 | Novartis Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| ES2109796T3 (es) | 1994-05-03 | 1998-01-16 | Ciba Geigy Ag | Derivados de pirrolopirimidilo con efecto antiproliferante. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| JP4249804B2 (ja) | 1995-04-03 | 2009-04-08 | ノバルティス・アクチエンゲゼルシャフト | ピラゾール誘導体およびその製造法 |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6140317A (en) | 1996-01-23 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE59710417D1 (de) | 1996-03-15 | 2003-08-14 | Novartis Ag | N-7 HETEROCYCLYL-PYRROLO[ 2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| AR007855A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| PT938486E (pt) | 1996-08-23 | 2008-03-27 | Novartis Ag | Pirrolopirimidinas substituídas e processos para a sua preparação |
| CA2266519C (en) | 1996-10-02 | 2007-01-23 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| WO1998014449A1 (en) | 1996-10-02 | 1998-04-09 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US6291496B1 (en) * | 1999-12-27 | 2001-09-18 | Andrew J. Dannenberg | Treating cancers associated with overexpression of class I family of receptor tyrosine kinases |
| CA2402525A1 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| US6500633B1 (en) * | 2000-04-26 | 2002-12-31 | Atairgin Technologies, Inc. | Method of detecting carcinomas |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US20060008823A1 (en) | 2004-05-12 | 2006-01-12 | Kemp Jennifer T | DNA profiling and SNP detection utilizing microarrays |
| AU2005250484B2 (en) * | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| ES2549769T3 (es) | 2009-03-25 | 2015-11-02 | Genentech, Inc. | Anticuerpos anti-FGFR3 y métodos que emplean los mismos |
| US20130059303A1 (en) * | 2011-09-06 | 2013-03-07 | Francois Radvanyi | Cdkn2a as a prognostic marker in bladder cancer |
| BR112015001724A2 (pt) | 2012-07-27 | 2018-04-03 | Genentech Inc | métodos de tratamento de condições relacionadas a fgfr3 |
| EP2912467A4 (en) * | 2012-10-26 | 2016-04-20 | Univ Queensland | METHOD FOR CLASSIFYING TUMORS AND USE THEREOF |
| WO2014135655A1 (en) * | 2013-03-06 | 2014-09-12 | Institut Curie | Compositions and methods for treating muscle-invasive bladder cancer |
| JP6309610B2 (ja) * | 2013-03-14 | 2018-04-11 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんを処置する方法 |
-
2015
- 2015-12-23 AU AU2015371312A patent/AU2015371312B2/en not_active Ceased
- 2015-12-23 KR KR1020177017321A patent/KR20170095893A/ko not_active Ceased
- 2015-12-23 WO PCT/US2015/000237 patent/WO2016105503A1/en not_active Ceased
- 2015-12-23 CA CA2969830A patent/CA2969830A1/en active Pending
- 2015-12-23 EP EP19212435.2A patent/EP3699290A1/en not_active Withdrawn
- 2015-12-23 MX MX2017008421A patent/MX394474B/es unknown
- 2015-12-23 MY MYPI2017000931A patent/MY188938A/en unknown
- 2015-12-23 SG SG11201704852SA patent/SG11201704852SA/en unknown
- 2015-12-23 EP EP15831090.4A patent/EP3237638B1/en active Active
- 2015-12-23 JP JP2017533956A patent/JP6900314B2/ja active Active
- 2015-12-23 HK HK18104105.4A patent/HK1244847A1/zh unknown
- 2015-12-23 RU RU2017125053A patent/RU2739942C2/ru active
- 2015-12-23 CN CN201580075170.9A patent/CN107223163A/zh active Pending
-
2017
- 2017-06-08 IL IL252796A patent/IL252796B/en unknown
- 2017-06-21 US US15/628,775 patent/US20170306418A1/en not_active Abandoned
-
2021
- 2021-06-15 JP JP2021099307A patent/JP2021169451A/ja active Pending
-
2022
- 2022-05-12 US US17/743,230 patent/US20220267864A1/en not_active Abandoned
-
2023
- 2023-01-20 US US18/157,597 patent/US20230220491A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zuo et al. | AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma | |
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| RU2017125053A (ru) | Терапевтические, диагностические и прогностические способы для рака мочевого пузыря | |
| Yoshimura et al. | EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib | |
| Cho et al. | Nilotinib in patients with metastatic melanoma harboring KIT gene aberration | |
| Jimeno et al. | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer | |
| Li et al. | The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere | |
| Seront et al. | Phase II study of dual phosphoinositol‐3‐kinase (PI 3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ 235 in patients with locally advanced or metastatic transitional cell carcinoma | |
| Spagnolo et al. | Upcoming strategies for the treatment of metastatic melanoma | |
| Brunner et al. | Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung | |
| Long et al. | Evaluation of KRAS inhibitor-directed therapies for pancreatic cancer treatment | |
| Gandara et al. | A phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non–small cell lung cancer | |
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| US20140199405A1 (en) | Method for treating cancer based on mutation status of k-ras | |
| JP2018513155A5 (enExample) | ||
| Jing et al. | Down-expression of miR-373 predicts poor prognosis of glioma and could be a potential therapeutic target | |
| Guigay et al. | Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance | |
| Yang et al. | Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients | |
| Park et al. | Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients | |
| Sulaiman et al. | Comprehensive overview of therapeutic strategies in Colon cancer: Chemotherapy, targeted therapy, and immunotherapy | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| Kim | Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches | |
| US20170079979A1 (en) | Therapy for solid tumors | |
| Castellani et al. | Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib | |
| RU2715551C1 (ru) | Способ прогнозирования эффективности неоадъювантной химиотерапии при тройном негативном раке молочной железы |